Trial Profile
A phase 2, 24-week, multicenter, randomized, parallel-group, dose-ranging study to evaluate the effect of teriparatide nasal spray on bone mineral density in postmenopausal women with low bone mineral density
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2019
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary) ; Teriparatide (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Adhera Therapeutics
- 21 Mar 2008 New trial record.